about
Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia.Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.Treatment of Newly Diagnosed Elderly Multiple Myeloma.Lenalidomide is safe and active in Waldenström macroglobulinemia.Impact of initial FDG-PET/CT and serum-free light chain on transformation of conventionally defined solitary plasmacytoma to multiple myeloma.IgMκ and IgMλ Measurements for the Assessment of Patients with Waldenström's Macroglobulinaemia.[Pomalidomide for multiple myeloma].[Smoldering multiple myeloma].IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.Mixed phenotype acute leukaemia with Burkitt-like cells and positive peroxidase cytochemistry.Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma.Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.G-CSF mobilizes CD34 + regulatory monocytes that inhibit graft-versus-host diseaseCarfilzomib Weekly 20/56mg/m , Lenalidomide and Dexamethasone for Early Relapsed Refractory Multiple MyelomaReduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimensConsolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma[Monoclonal gammopathies of undetermined significance do not systematically require a specialized consultation]Serotonin, hematopoiesis and stem cellsCarfilzomib Weekly plus Melphalan and Prednisone in Newly Diagnosed Transplant-Ineligible Multiple Myeloma (IFM 2012-03): A Phase I TrialResponse to pneumococcal vaccination in multiple myeloma
P50
Q38065298-8A8B9FE8-01B9-4D3B-B142-0756989899F7Q38087742-13ADE24A-EAAA-4BE5-AD02-083020EC98CEQ38373226-972F7BA2-32E1-4E9C-8B26-92394AD22E94Q38736404-78EAA75D-BAC2-49E7-9922-9FFD2653CA0BQ38815405-C50AC169-F93F-47C3-B638-0EF40079AD34Q38973119-3A06AAD6-88C3-43C7-8D46-736F2555FCA7Q39213370-93883286-CAAB-4229-AEF1-9207A9DE19F7Q40678259-A90E85EA-32D9-49F9-9E18-EA552B516D6FQ41499587-25A22274-8F53-43CC-AEC9-7B5BB1685427Q44658495-84B432EC-087A-47EB-85BB-3C122CDD1FF3Q44818652-E034D3F9-CA00-42A5-9B82-F874911FC7BBQ44962377-5FB7E353-90C2-415F-8064-DE2742D4D5C2Q45792742-59B16F6F-8FA1-405B-B386-CE9DE30D0482Q48250873-EE905D4C-C443-48DA-B249-BCD1428C1A56Q53203181-8BDDFB24-DF4F-4999-8DD3-68F563F3BB60Q57216806-CC90767C-C2D0-4A89-9467-DE2BB9715AEFQ57784502-5C0A270C-533B-45F4-820D-C109168E70B8Q84212818-77BF70FD-2074-49FA-BC27-34D5BBED3A51Q86543759-83A8A0FC-9D24-4760-A190-E516008B4FB4Q86549809-9BB34513-752D-4797-B520-104B60DE67BBQ90941951-12DD18DE-9472-49FA-A6C7-6B9E897C9F30Q91750643-B5481E7E-1D37-4C7B-972D-6EC1569658F6Q92402845-E2278B4F-266A-4996-88C0-12044A95CF5D
P50
description
researcher ORCID ID = 0000-0002-3751-393X
@en
wetenschapper
@nl
name
Guillemette Fouquet
@ast
Guillemette Fouquet
@en
Guillemette Fouquet
@es
Guillemette Fouquet
@nl
type
label
Guillemette Fouquet
@ast
Guillemette Fouquet
@en
Guillemette Fouquet
@es
Guillemette Fouquet
@nl
prefLabel
Guillemette Fouquet
@ast
Guillemette Fouquet
@en
Guillemette Fouquet
@es
Guillemette Fouquet
@nl
P31
P496
0000-0002-3751-393X